Organon & Co. (NYSE:OGN) Receives Consensus Rating of “Reduce” from Brokerages

Shares of Organon & Co. (NYSE:OGN) have earned an average recommendation of “Reduce” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $8.3750.

A number of equities analysts recently commented on OGN shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. Barclays assumed coverage on Organon & Co. in a report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price target on the stock. JPMorgan Chase & Co. reduced their price target on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research report on Tuesday, November 11th. Morgan Stanley decreased their price objective on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 11th. Finally, Wall Street Zen upgraded Organon & Co. from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd.

Institutional Investors Weigh In On Organon & Co.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hanson & Doremus Investment Management acquired a new stake in Organon & Co. in the second quarter valued at approximately $26,000. Hantz Financial Services Inc. lifted its holdings in shares of Organon & Co. by 293.8% during the 2nd quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock valued at $26,000 after purchasing an additional 1,995 shares during the last quarter. Foster Dykema Cabot & Partners LLC acquired a new stake in shares of Organon & Co. in the 3rd quarter worth $29,000. SouthState Corp grew its stake in Organon & Co. by 1,857.0% during the 2nd quarter. SouthState Corp now owns 3,914 shares of the company’s stock worth $38,000 after buying an additional 3,714 shares during the last quarter. Finally, Rothschild Investment LLC grew its stake in Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after buying an additional 1,646 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Down 1.3%

Shares of Organon & Co. stock opened at $8.03 on Friday. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20. Organon & Co. has a 1 year low of $6.18 and a 1 year high of $17.23. The firm’s 50-day moving average is $7.29 and its two-hundred day moving average is $8.83. The stock has a market cap of $2.09 billion, a price-to-earnings ratio of 4.18, a PEG ratio of 1.67 and a beta of 0.58.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The business had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the business posted $1.38 EPS. As a group, research analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th were issued a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Thursday, November 20th. Organon & Co.’s dividend payout ratio (DPR) is currently 4.17%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.